Literature DB >> 9670958

HLA class II expression in uninducible hepatocarcinoma cells after transfection of AIR-1 gene product CIITA: acquisition of antigen processing and presentation capacity.

S Sartoris1, M T Valle, A L Barbaro, G Tosi, T Cestari, A D'Agostino, A M Megiovanni, F Manca, R S Accolla.   

Abstract

The AIR-1-encoded CIITA transcriptional activator is crucial for both constitutive and IFN-gamma-induced MHC class II gene transcription. We show here that the MHC class II negative phenotype of the human hepatocarcinoma cell lines Alexander and HepG2 remains unmodified after treatment with IFN-gamma, although MHC class I expression is up-modulated. This correlates with absence of CIITA mature transcripts. Transfection of an expressible CIITA cDNA in Alexander cells resulted in a very high cell surface expression of all three human class II subsets, HLA-DR, -DP and -DQ, indicating that normally observed induction of CIITA expression by IFN-gamma is probably blocked, in the hepatocarcinoma cell lines, at the level of CIITA transcription and not at the level of IFN-gamma receptor binding and signal transduction mechanisms. To assess whether MHC class II expression on CIITA-transfected Alexander cells could have functional relevance, we tested their capacity to present antigenic peptides to an HLA-DR-restricted T cell line specific for a peptide of Mycobacterium tuberculosis Ag85 protein. It was found that the transfected cells could not only present the exogenously supplemented peptide but also process Ag85 protein to generate the specific epitope recognized by the HLA-DR-restricted T cell line. Similar results were obtained with CIITA-transfected CFPAC-1 pancreatic adenocarcinoma cells, which differed from Alexander cells in that they were inducible by IFN-gamma. These results suggest new strategies to act on CIITA for increasing the potential of a tumor cell to present putative tumor Ags to the immune system.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9670958

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  18 in total

Review 1.  Class II transactivator: mastering the art of major histocompatibility complex expression.

Authors:  J A Harton; J P Ting
Journal:  Mol Cell Biol       Date:  2000-09       Impact factor: 4.272

Review 2.  Novel mechanisms of class II major histocompatibility complex gene regulation.

Authors:  Michael Radosevich; Santa Jeremy Ono
Journal:  Immunol Res       Date:  2003       Impact factor: 2.829

3.  CIITA-driven MHC class II expressing tumor cells can efficiently prime naive CD4+ TH cells in vivo and vaccinate the host against parental MHC-II-negative tumor cells.

Authors:  Farah Bou Nasser Eddine; Greta Forlani; Letizia Lombardo; Alessandra Tedeschi; Giovanna Tosi; Roberto S Accolla
Journal:  Oncoimmunology       Date:  2016-11-28       Impact factor: 8.110

Review 4.  Biological Consequences of MHC-II Expression by Tumor Cells in Cancer.

Authors:  Margaret L Axelrod; Rebecca S Cook; Douglas B Johnson; Justin M Balko
Journal:  Clin Cancer Res       Date:  2018-11-21       Impact factor: 12.531

Review 5.  Specific immunotherapy of cancer in elderly patients.

Authors:  S Matzku; M Zöller
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

6.  IFN-γ induces the upregulation of RFXAP via inhibition of miR-212-3p in pancreatic cancer cells: A novel mechanism for IFN-γ response.

Authors:  Guoping Ding; Liangjing Zhou; Tao Shen; Liping Cao
Journal:  Oncol Lett       Date:  2018-01-12       Impact factor: 2.967

7.  Relationship between polymorphism of class II transactivator gene promoters and chronic hepatitis B.

Authors:  Ying-Ren Zhao; Ling Gong; Ying-Li He; Fang Liu; Chang Lu
Journal:  World J Gastroenterol       Date:  2005-02-14       Impact factor: 5.742

8.  CIITA-related block of HLA class II expression, upregulation of HLA class I, and heterogeneous expression of immune checkpoints in hepatocarcinomas: implications for new therapeutic approaches.

Authors:  Elise Ramia; Anna Maria Chiaravalli; Farah Bou Nasser Eddine; Alessandra Tedeschi; Fausto Sessa; Roberto S Accolla; Greta Forlani
Journal:  Oncoimmunology       Date:  2018-11-26       Impact factor: 8.110

Review 9.  Adequate antigen availability: a key issue for novel approaches to tumor vaccination and tumor immunotherapy.

Authors:  Roberto S Accolla; Giovanna Tosi
Journal:  J Neuroimmune Pharmacol       Date:  2012-12-07       Impact factor: 4.147

Review 10.  Optimal MHC-II-restricted tumor antigen presentation to CD4+ T helper cells: the key issue for development of anti-tumor vaccines.

Authors:  Roberto S Accolla; Giovanna Tosi
Journal:  J Transl Med       Date:  2012-07-31       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.